Joint Development of Companion Diagnostics and Global Business Partnership with QIAGEN
First written in FY2022-Q2. 2 of 4 entries say "Restated". Latest entry: FY2025-H1.
0 other companies' latest entry also says "Raised".
- FY2025-H1RaisedAnnual report
「In addition, the company agreed with QIAGEN N.V. (hereinafter, "QIAGEN") to strengthen multifaceted cooperation in the genetic testing field, including research and development, production, clinical development and sales, and entered into a global alliance agreement. Through this agreement, the two companies will further deepen their cooperation, accelerate their global success by working together to commercialize products in the genetic testing field in regions where each has strengths, and also consider future collaboration in product development.」
The company expanded the scope of its collaboration from the previous alliance in oncology companion diagnostics to a global alliance covering research and development, production, clinical development and sales in the genetic testing field. - FY2023RestatedAnnual report
「In the personalized medicine field, which is expected to deliver significant growth in the future, the company will develop new test parameters using its strengths in liquid biopsy technologies for genes, cells and proteins.」
The company has restated its policy of using companion diagnostics and liquid biopsy technologies in the personalized medicine field. - FY2022-Q3RestatedAnnual report
「⑦ July 2021: The company agreed with QIAGEN N.V. (QIAGEN) to a strategic business alliance covering the joint development of companion diagnostics in oncology and global business activities.」
The company has restated its agreement with QIAGEN N.V. on the joint development of companion diagnostics and a global business alliance as an achievement in its research and development activities. - FY2022-Q2First statedAnnual report
「In the life sciences field, the company agreed to a strategic business alliance with QIAGEN N.V. (hereinafter, "QIAGEN"), which has extensive experience developing companion diagnostics in oncology, covering joint development and global business activities. By leveraging QIAGEN's experience in companion diagnostics development, the company will strengthen collaboration with pharmaceutical companies globally and work toward the early development and clinical implementation of companion diagnostics.」
The company agreed to a strategic business alliance with QIAGEN N.V. for the joint development of companion diagnostics in oncology and global business activities. It is stating for the first time its policy of using QIAGEN's development experience to strengthen collaboration with pharmaceutical companies and advance early development and clinical implementation.